Checkin com:s vd om kursrusningen privataaffarer.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from privataaffarer.se Daily Mail and Mail on Sunday newspapers.
Online providers ramp up vaccinations to allay consumer fears
22 May, 2021 - 09:32 AM IST | By indiantelevision.com Team
Mumbai: E-commerce companies have launched a rampant vaccination drive for their frontline staffers and delivery partners who interface with consumers who worry about possible transmission of the newer and more virulent strains of Covid-19.
This comes in the wake of most e-tailer and logistics firms reporting infections among their frontline staffers who are on daily delivery missions of food and essential products such as medicines, healthcare packages and much more.
While these customer interfacing personnel busily operated for the better part of the last 14 months, even in the wake of the pandemic, newer and more virulent strains currently in vogue for their high transmitting potential are a constant source of discouragement for customers who got used to remotely ordering the doorstep delivery of their various needs as they stayed l
Atomized, an early-stage startup that wants to create a modern tool to help developers deploy infrastructure faster, announced the first step of its funding journey today, a $500,000 pre-seed round from Zing Capital, Y Combinator and several unnamed angels. Company co-founder and CEO Nik Kotov says developers are spending over 20% of their time on setting up the necessary infrastructure just to run their applications, and he and his co-founder and CTO Eddie Herbert believed there had to be a better way, so like all good entrepreneurs, they built one. "Our [goal] is actually to abstract away all those choices, all those nitty gritty details of Amazon, Azure and GCP and essentially provide you the easiest most straightforward solution," he said.
Share:
BOSTON, April 28, 2021 /PRNewswire/ Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal
Cell by Delix Co-founder and Chief Scientific Officer, Professor David E. Olson, PhD.
The paper, co-authored by Olson and collaborator Lin Tian, PhD, both of whom are professors at the University of California, Davis, reveals DLX-1 a new compound inspired by the chemical structures of common psychedelic substances that demonstrates sustained antidepressant effects but without hallucinogenic properties. DLX-1 also known as AAZ is the second published example of a non-hallucinatory Delix Therapeutics compound capable of achieving rapid and sustained therapeutic efficacy in preclinical animal models. Preclinical results for DLX-7, also known as TBG, were published in
Share this article
Share this article
BOSTON, April 28, 2021 /PRNewswire/ Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal
Cell by Delix Co-founder and Chief Scientific Officer, Professor David E. Olson, PhD.
The paper, co-authored by Olson and collaborator Lin Tian, PhD, both of whom are professors at the University of California, Davis, reveals DLX-1 a new compound inspired by the chemical structures of common psychedelic substances that demonstrates sustained antidepressant effects but without hallucinogenic properties. DLX-1 also known as AAZ is the second published example of a non-hallucinatory Delix Therapeutics compound capable of achieving rapid and sustained therapeutic efficacy in preclinical animal models. Preclinical results for DLX-7, also known as TBG, were published in